CORAL SPRINGS, Fla., Aug. 6, 2009 (GLOBE NEWSWIRE) -- CyGene Laboratories Inc. (Pink Sheets:CYGE) announced today that it is introducing an alcohol-dependence genetic profile product for the Eurasian market.
The company recently announced that it is providing direct-to-consumer predictive genetic products in the Russian Federation through its exclusive licensee CyGene Russia, LLC (www.cygenedirect.ru) and is expecting to expand its presence in Eastern Europe and Asia.
The new alcohol-dependence product analyzes variations in seven genes known to be associated with an increased risk for excessive alcohol consumption, substance abuse and some of the related complications with these behaviors. It is targeted geographically to the Eurasian market, because the genes chosen for the test panel relate to the ethnic composition of the region.
"This new product fits with CyGene's mission of providing genetic tests that are based on solid science, and that provide information that people can actually use to improve their lives," said Martin Munzer, CyGene's president and CEO.
"Scientific research is showing that genetics plays an important role in the progression and treatment of alcoholism. Variations in the tested genes have been associated with alcohol metabolism, detoxification, brain stimulating effects and the conferred increased risk for excessive substance and alcohol consumption, as well as increased risk for alcohol-related damage to the liver and pancreas," he continued.
CyGene currently markets a variety of DNA predictive genetic test panels that provide consumers with information on genetic predisposition to treatable conditions. CyGene is the only consumer genetic testing provider that guarantees anonymity to its customers, while providing access to the most updated science at the lowest possible price. The new Alcohol Dependence DNA Analysis is priced at $130 retail. Distributors are being recruited throughout the region and are invited to contact CyGene for information on how they can participate in the sale of CyGene's products.
About CyGene Laboratories Inc.
CyGene Laboratories Inc., based in Coral Springs, Fla., is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets eight DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available.
For more information about CyGene Laboratories and its products, visit the Company's Web site at www.CyGeneDirect.com.
The CyGene Laboratories Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6480